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Summary
INTRODUCTION: In Switzerland, the outcome of vascular
access creation in the 4500 current dialysis patients is un-
known, mainly because there is no prospective registry for
patients undergoing vascular access surgery for renal re-
placement therapy. The aim of the study was to assess
the quality of vascular access creation and to compare it
with the current literature and guidelines, in order to define
strategies to improve clinical outcome.
METHODS: Retrospective single-centre study in a tertiary
referral centre. All consecutive patients over 18 years of
age undergoing primary vascular access creation between
January 2013 and December 2014 were included. Follow-
up data for at least 12 months were collected.
RESULTS: During the study period, 365 patients had a
surgical intervention for renal replacement therapy. A pri-
mary vascular access was created in 74 patients (20%),
who were further analysed in our study: 63 (85%) had an
arteriovenous fistula (AVF) and 11 (15%) an arteriovenous
graft (AVG). The intervention-free survival (primary paten-
cy rate) of the primary vascular access at 1 year was 46%
(95% confidence interval [CI] 33–58%) for AVF and 30%
(95% CI 7–58%) for AVG, with a secondary patency rate at
1 year of 75% (95% CI 63–84%) for AVF and 50% (95% CI
18–75%) for AVG. Twenty-seven patients (36%) with pri-
mary vascular access underwent central venous catheter
(CVC) placement (tunnelled or non-tunnelled) before the
access creation. Thirty-seven (50%) patients had their first
dialysis through a CVC. Thirty-one patients (42%) never
received a CVC.
CONCLUSIONS: The primary patency of vascular access
was unexpectedly low, and the number of CVC requests
unexpectedly high. In light of this, we consider it essential
that centres creating vascular access should register their
activities and compare their outcomes with current guide-
lines to check and improve clinical management. To facili-
tate this, there is an initiative starting in 2018 encouraging
all Swiss vascular surgeons to provide data on vascular
access interventions, including 1-year follow-up, in the na-
tional online registry “SwissVasc 2.0”.
Keywords: outcome of primary vascular access for dialy-
sis, arteriovenous fistula, arteriovenous graft, primary pa-
tency of vascular access for dialysis, guidelines vascular
access
Introduction
Functional vascular access, most commonly an arteriove-
nous fistula (AVF) or an arteriovenous graft (AVG), is es-
sential to deliver adequate haemodialysis therapy to pa-
tients. The need for dialysis in patients with chronic kidney
disease has been increasing in recent years [1]. Between
1990 and 2000, the global prevalence of maintenance dial-
ysis increased 1.7 times and the incidence more than dou-
bled [2]. Therefore, efficient vascular access creation and
maintenance service is essential. With an average life ex-
pectancy of patients on dialysis of 5 to 10 years, vascular
access longevity is an important issue and unfortunately
can be jeopardised by various issues [3]. Non-maturation,
occlusion and infection are typical complications occurring
during the evolution of the vascular access. This results in
frequent surgical revisions and an increased use of central
venous catheters (CVCs) as an alternative for haemodialy-
sis access, which in turn is related to higher morbidity and
mortality rates and increased costs [4–8]. The primary pa-
tency of a vascular access, which represents intervention-
free survival, has been reported to be superior for AVFs
[9–13], with AVGs and CVCs showing a reduced interven-
tion-free survival. There is conflicting evidence in the lit-
erature as to primary AVF creation rates, ranging from 24
to 80% [14], and the percentage of patients on CVC dialy-
sis is reported to be nearly 80% [15].
The optimal surgical management is to create an AVF, and
avoid grafts and CVCs for as long as possible. It remains
unclear whether this aim is being achieved in current prac-
tice. Vascular access guidelines such as the Kidney Dis-
eases Outcomes Quality Initiative (K/DOQI) [16], Euro-
pean Renal Best Practice Guidelines [14] and the Clinical
Practice Guidelines of the European Society for Vascular
Surgery (ESVS) [17] address this issue.
The United States Renal Data System (USRDS) collects
data from national and regional renal registries in the USA
[1]. However, Switzerland does not have a specific multi-
disciplinary registry for vascular access and outcome data
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for vascular access creation is not available, although more
than 4500 patients are currently on haemodialysis in this
country [18]. This means that we cannot compare our re-
sults with other centres and countries or review conformity
with guidelines.
The aim of this retrospective study was to assess the qual-
ity of vascular access creation in a Swiss tertiary referral
centre and to compare it with the current literature and
guidelines to define strategies to improve the clinical man-
agement process (fig. 1).
Methods
This retrospective analysis was designed as a quality con-
trol study of a tertiary referral centre in Switzerland, in ac-
cordance with the Helsinki declaration. All consecutive pa-
tients >18 years old undergoing primary vascular access
creation between January 2013 and December 2014 were
included. Other interventions for renal replacement thera-
py during this time (isolated catheters for peritoneal dialy-
sis, CVCs without simultaneous access creation, secondary
vascular access creation and vascular access revisions)
were taken into account but not further analysed. Data, in-
cluding demographics, risk factors, comorbidities, surgi-
cal details, outcome parameters and follow-up information,
were retrieved from the hospital records of the Department
of Cardiovascular Surgery and the Department of Nephrol-
ogy and Hypertension. We contacted external dialysis units
for information on patients followed up at other institu-
tions. Primary vascular access was classified as AVF or
AVG, as well as according to its anatomical location. Study
data were collected and managed using REDCap research
electronic data capture hosted at the institution (REDCap
Software, Version 6.9.3, Vanderbilt University). Follow-up
data for at least 365 days were collected. Data were col-
lected in a retrospective manner as part of the in-hospital
quality control, which is regulated by the federal law for
health insurance. Primary endpoints of the study were the
primary and the secondary patency after 1 year. Secondary
endpoints were reinterventions and CVC placement.
Proportions and 95% confidence intervals (CIs) of primary
and secondary endpoints at 1 year after vascular access
were calculated to compare the treatment groups using
the chi-squared test. The Kaplan-Meier method was used
to estimate freedom from events with respect to all end-
points during the entire follow-up time. Hazard ratios and
Figure 1: Vascular access creation (brachiocephalic arteriovenous
fistula) using a punch.
95% CIs were analysed using Cox regression analysis. The
proportional hazard assumption was tested on Schoenfeld
residuals. All CIs are two-sided. Statistical analyses were
performed using Stata 12 (StataCorp LP, College Station,
Tx, USA).
The ESVS definitions of primary and secondary patency
were applied [17]. In brief, primary patency is the time
between access creation and the first reintervention. Sec-
ondary patency is the time between access creation and
abandonment after one or more reinterventions.
Results
General aspects
Between January 2013 and December 2014, there were
365 surgical interventions for renal replacement therapy
(fig. 2). Revision surgery represents the largest group (n =
163), followed by CVC placement (n = 78), including 45
exchanges from a non-tunnelled to a tunnelled CVC, 15
isolated tunnelled CVCs and 18 CVC removals. Seventy-
four patients with a primary vascular access creation were
included in the further analysis: 11 AVG and 63 AVF. Nine
patients with a primary access were excluded because of
renal transplantation (three), operative abandonment of ac-
cess (four), no further dialysis required (one), and patient
refusal of revision of a failing vascular access (one).
All patients had preoperative venous and arterial ultra-
sound mapping. The surgeons’ experience was as follows:
trainees under supervision (15) and board-certified sur-
geons (59). Type of anaesthesia used was: local (2), region-
al (53), and general (19).
Figure 2: Overview of interventions for renal replacement therapy
January 2013 to December 2014.AVF = arteriovenous fistula; AVG
= arteriovenous graft; BBAVF = brachiobasilic AVF, upper arm;
BCAVF = brachiocephalic AVF, upper arm; RCAVF =radiocephalic
AVF (Cimino), forearm; UCAVF = ulnocephalic AVF forearm and
upper arm; VA = vascular access145 changes (2 non-tunnelled), 18
removals, (3 non-tunnelled), 15 new inserted (2 non-tunnelled)
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Demographics
Table 1 shows demographic data and comorbidities of pa-
tients with a primary vascular access creation. The most
common cause of end-stage renal disease was hypertensive
nephropathy (36%).
Follow-up and Survival
Mean follow-up ± standard deviation was 564 ± 294 days.
The survival curve is shown in fig. 3. Mortality at 1 year
was 11%.
Primary patency rate
The intervention-free primary patency rate of the vascular
access at 1 year was 46% (95% CI 33–58%) for AVF
and 30% (95% CI 7–58%) for AVG (fig. 4). There was
no significant difference in primary patency rate between
AVG and AVF either in the upper arm (30%, 95% CI
7–58% vs 46%, 95% CI 24–66%, respectively; p = 0.384)
Figure 3: Patient survival after vascular access creation (including
95% confidence intervals): median survival 528 days (interquartile
range 371–807).
or in the forearm (30%, 95% CI 7–58% vs 46%, 95%
CI 30–60%, respectively; p = 0.813). A Cox regression
analysis showed hazard ratios for primary patency of 0.91
(95% CI 0.41–1.99) for forearm AVF and 0.68 (95% CI
0.28–1.66) for upper arm AVF, when compared with AVG.
Secondary patency rate and reinterventions
The secondary patency rate of the vascular access at 1 year
was 75% (95% CI 63–84%) for AVF and 50% (95% CI
18–75%) for AVG (fig. 5). A trend to a better secondary
patency rate at 1 year was seen with AVF in the upper
arm (80%, 95% CI 56–92%) as compared with AVF on
the forearm (73%, 95 CI 56–84%; p = 0.322). A Cox re-
gression analysis showed hazard ratios for secondary pa-
tency of 0.77 (95% CI 0.28–2.12) for forearm AVF and
0.46 (95% CI 0.13–1.6) for upper arm AVF, when com-
pared with AVG.
Table 2 shows revisions performed during the follow-up.
Twenty-four percent (16/68) of all revisions were per-
Figure 4: Primary patency of primary vascular access: median pri-
mary patency 253.5 days (interquartile range 92–453).AVF = arte-
riovenous fistula; AVG = arteriovenous graft
Table 1: Demographics and comorbidities.
All patients
(n = 74)
AVG
(n = 11)
AVF forearm
(n = 42)
AVF upper arm
(n = 21)
General
Female, n (%) 27 (36) 7 (64) 12 (29) 8 (38)
Age in years (mean ± SD) 62.9 ± 15.9 62.9 ± 12.5 60.9 ± 16.1 66.7 ± 16.8
BMI in kg/m2 (mean SD) 27.8 ± 5.5 29.3 ± 6.5 28.7 ± 5.4 25.1 ± 4.3
Creatinine in μmol/l* (mean ± SD) 434 ± 254 449 ± 348 480 ± 265 336 ± 126
Estimated creatinine clearance rate† in ml/min/1.73m2 (mean ±SD) 16.7 ± 7.9 18.4 ± 11.7 15.9 ± 6.8 17.4 ± 7.6
Cause of ESRD‡
Hypertensive nephropathy, n (%) 27 (36) 6 (55) 13 (31) 8 (38)
Diabetic nephropathy, n (%) 26 (35) 6 (55) 11 (26) 9 (43)
Glomerulonephritis, n (%) 9 (12) 1 (9) 5 (12) 3 (14)
Systemic inflammatory disease and vasculitis (e.g., SLE), n (%) 8 (11) 0 (0) 4 (10) 4 (19)
Hereditary nephropathy, n (%) 7 (9) 2 (18) 4 (10) 1 (5)
Others, n (%) 7 (9) 0 (0) 5 (12) 2 (10)
Unknown, n (%) 7 (9) 0 (0) 2 (5) 5 (24)
Tubulointerstitial nephritis, n (%) 4 (5) 2 (18) 2 (5) 0 (0)
Vascular nephropathy, n (%) 3 (4) 0 (0) 2 (5) 1 (5)
Risk factors‡
Hypertension, n (%) 70 (95) 11 (100) 40 (95) 19 (90)
Dyslipidaemia, n (%) 45 (61) 7 (64) 25 (60) 13 (62)
Diabetes mellitus, n (%) 36 (49) 7 (64) 16 (38) 13 (62)
Smoking, n (%) 26 (35) 3 (27) 16 (38) 7 (33)
AVF = arteriovenous fistula: AVG = arteriovenous graft; BMI = body mass index; ESRD = end-stage renal disease; SLE = systemic lupus erythematosus * At time of access
creation † Cockroft-Gault ‡ Multiple selections possible
Original article Swiss Med Wkly. 2018;148:w14668
Swiss Medical Weekly · PDF of the online version · www.smw.ch
Published under the copyright license “Attribution – Non-Commercial – No Derivatives 4.0”.
No commercial reuse without permission. See http://emh.ch/en/services/permissions.html.
Page 3 of 6
formed before the vascular access was used for dialysis.
Forty-one patients needed one revision, 19 patients two re-
visions and 8 patients three revisions.
Patients with AVG (72%) underwent more revisions com-
pared with upper arm AVF (57%) and forearm AVF (50%).
Thrombosis was the main reason for AVG revisions and
stenosis for AVF revisions. Forearm AVF had more revi-
sions due to thrombosis than upper arm AVF. Infection was
observed in only one AVG. Other reasons for reoperations
were banding of a high-flow fistula (one), ligation of side
branches (two), intervention to correct a lymphocele (one),
transposition of cephalic vein (one), and aneurysm ligation
(one).
Reasons for abandonment of vascular access (31/74) were
the following: spontaneous thrombosis/occlusion (12), re-
nal transplantation (7), and death (4). Other reasons for
abandonment were non-maturation (four), stenosis and
hand ischaemia (two), stenosis and aneurysm (one) and
multiple stenoses (one).
CVC placement
Twenty-seven patients (36%) underwent CVC placement
(tunnelled or non-tunnelled) before vascular access cre-
ation. Of these, the CVC was removed in 13 (48%) patients
during the first postoperative year. Of the 47 patients who
did not have a CVC beforehand, 7 (15%) simultaneously
received a CVC during vascular access creation and 9
Figure 5: Secondary patency of primary vascular access: median
secondary patency 458 days (interquartile range 223–767). AVF =
arteriovenous fistula; AVG = arteriovenous graft
(17%) received a CVC during the first year. Only 31 pa-
tients (42%) never received a CVC (fig 6.)
Thirty-seven (50%) patients had their first dialysis through
a CVC. Only 19 (26%) patients had their first dialysis over
an AVF and four (5%) over an AVG. At the cut-off of 365
days after surgery, 12 (16%) patients had not undergone
dialysis through a catheter or a vascular access (10 AVF / 2
AVG) and 17 (23%) patients were still dialysed via a CVC.
During the follow-up, in 14 patients with an AVF and in
3 patients with an AVG, the primary vascular access was
never used for dialysis.
In patients with a primary AVF or AVG, the total amount
of time for which a CVC was present was 380 ± 474 days
(395 ± 495 days for AVF vs 262 ± 269 for AVG), which
includes the pre- and post-vascular access creation period.
Discussion
During the 2-year observation period, approximately one
fifth of all surgical interventions in the field of renal re-
placement therapy at our tertiary hospital were related to
primary vascular access creation. Nearly half of this opera-
tive case-load dealt with vascular access revisions and an-
other fifth with interventions for tunnelled CVC. Eighty-
five percent of creations of primary native (autologous)
vascular access was in accordance with the guidelines and
reflects our policy to favour the construction of an AVF
over an AVG [16]. In the case of missing forearm veins, a
Figure 6: central venous catheter placement in combination with
vascular access creation (including 95% confidence intervals).AVF
= arteriovenous fistula; AVG = arteriovenous graft
Table 2: Revisions during the follow-up.
All patients
(n = 74)
AVF forearm
(n = 42)
AVF upper arm
(n = 21)
AV graft
(n = 11)
p-value*
No. of revisions per 1000 patient days (95%
CI)
1.7
(1.33–2.15)
1.51
(1.05–2.10)
1.46
(0.87–2.31)
2.87
(1.70–4.54)
0.755
For bleeding 0.07
(0.01–0.21)
0.04
(0.00–0.24)
0.08
(0.00–0.45)
0.16
(0.00–0.89)
0.755
For stenosis 0.77
(0.52–1.08)
0.82
(0.49–1.28)
0.97
(0.50–1.70)
0.16
(0.00–0.89)
0.227
For thrombosis 0.67
(0.45–0.97)
0.43
(0.21–0.79)
0.24
(0.05–0.71)
2.39
(1.34–3.94)
0.017
For infections 0.02
(0.00–0.13)
0
(0.00–0.16)
0
(0.00–0.30)
0.16
(0.00–0.89)
0.632
For other reasons 0.17
(0.07–0.35)
0.22
(0.07–0.50)
0.16
(0.02–0.59)
0
(0.00–0.59)
0.559
AVF = arteriovenous fistula; AVG = arteriovenous graft; CI = confidence interval * p-value between AVG and the total of AVF (forearm and upper arm combined)
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loop graft can be helpful to preserve and remodel the up-
per arm veins before cubital AVF creation is considered
[19–21]. There is an ongoing discussion as to whether for
elderly patients with poor veins and a limited life expectan-
cy, the implantation of AVG is a better option than an AVF
creation, with the risk of non-maturation and the interim
need for a CVC [10].
Patients with end-stage renal disease have a high preva-
lence of risk factors, related to a high percentage of co-
morbidities, particularly cardiovascular. Advanced age and
poor vessel quality may be another reason why AVF matu-
ration is a problem leading to several reinterventions even
before the vascular access is in use.
The mortality from chronic kidney disease increased by
82% between 1990 and 2010 and accounts for a significant
proportion of mortality in the world. This risk is dependent
on the stage of the chronic kidney disease and is related to
coronary heart disease [22]. Not surprisingly, this applies
to our cohort with an average age of 63 years and a follow-
ing drop in the survival curve.
Current literature shows a high percentage of non-matu-
ration [23, 24], related to the fact that older patients and
patients with more comorbidities are dialysed. In addition,
surgeons try to promote AVF creation, even when the ves-
sel quality seems poor. Maybe a more consistent preoper-
ative ultrasound algorithm, based not only on the absolute
arterial inner diameter, but also on the measurement of the
arterial wall distensibility, could help to improve the pre-
dictability of AVF maturation [25, 26].
We observed a substantial difference in the 1-year results
between the primary and the secondary patency. The pri-
mary patency rate was below our expectations and below
the range of 52 to 83% reported in the literature. A Cox re-
gression analysis did not show a significant difference be-
tween AVG and AVF.
On one hand, further investigation is needed to identify pa-
tients who are at risk for AVF non-maturation or early ac-
cess failure. This is important in the context of a “fistula
first” approach where surgeons are advised to create a fore-
arm AVF instead of an AVG or upper arm AFV; even if the
vessel quality is limited. On the other hand, we need im-
proved judgement of what kind of primary access should
be realised first.
Our secondary patency rates for AVF in the forearm or up-
per arm or for AVG is in accordance with results in the
literature; showing a secondary patency for radio-cephalic
AVF between 42-83% and for upper arm AVF of 47-88%
[17].
This poor outcome with a consecutive need of revisions is
a psychological burden for the patient and brings addition-
al costs to the healthcare system.
It is well documented that the use of CVC has a higher
morbidity and mortality [27]. Nevertheless, we recorded
CVC use in up to 60% of all patients with a primary access,
which is consistent with other reports [6].
In a report of from the ERA-EDTA (European Renal As-
sociation – European Dialysis and Transplant Association)
registry, including 13,044 patients, an increase of CVC use
to start haemodialysis from 58% in 2005 to 68% in 2009
was documented. In contrast, there was a reduction from
42 to 32% in the use of AVF as first-line vascular ac-
cess [28]. In our series, 50% of all patients started their
haemodialysis with a CVC. Since 36% of the CVCs were
implanted before vascular access creation, this could be
due to either late referral or difficulties to correctly predict
optimal timing of vascular access creation. Concerning
vascular access readiness for dialysis, the timing of vascu-
lar access creation and the risk of AVF non-maturation is
key. Early referral is recommended: 6 months for AVF and
at least 4 to 6 weeks for AVG. The increasing number of
patients requiring chronic renal replacement therapy after
acute kidney injury will continue to challenge optimal tim-
ing of vascular access creation. However, this inevitably
can also lead to patients undergoing surgery too early, de-
spite not requiring dialysis, as observed in our series.
This was a retrospective single-centre study with a small
number of patients and medium-term follow-up, which
limits comparison between the groups and generalisability
of the results. The comparison of data of forearm and upper
arm vascular access can be crucial when defined by the
area of cannulation. The brachial artery in the antecubital
fossa can give inflow for a forearm loop graft, as well as
for an upper arm cephalic or basilic AVF. Therefore, the
definition of the inflow vessel may be a more accurate way
to categorise the vascular access than the topography of
cannulation.
We assume that the group of patients in our tertiary referral
centre have more concomitant diseases than those in small-
er peripheral hospitals. For the analysis of intervention-
free survival, the bias of different endpoints i.e., revisions,
loss of vascular access and death, must be considered. Be-
cause of difficulties with documentation of dialysis data, it
was assumed that whenever there had been a CVC place-
ment, the patient was undergoing dialysis. Owing to lack
of data, acute, acute-on-chronic and chronic kidney failure
could not be differentiated in detail.
Conclusions
The primary patency in primary vascular access creation in
our centre was lower than expected when compared to the
literature, whereas the secondary patency was similar. The
percentage of CVCs implanted for dialysis was alarmingly
high and this needs to be addressed in the future, especially
with regard to the ideal timing of vascular access creation.
The vascular access team should implement the evidence
of guidelines. There is an initiative starting this year to en-
courage all Swiss vascular surgeons to provide data on vas-
cular access interventions, including 12-month follow-up,
in the national online registry “SwissVasc 2.0”.
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